Correlation Between Use of Antiretroviral Adherence Devices by HIV-Infected Youth and Plasma HIV RNA and Self-Reported Adherence

AIDS and Behavior

Volumn 19, Issue 1, 2015, Pages 93-103

  Saberi, Parya ^a   Mayer, Kenneth ^b   Vittinghoff, Eric ^a   Naar King, Sylvie ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence devices; Adolescent; Antiretroviral medication adherence; HIV; Youth

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADOLESCENT BEHAVIOR; ATTITUDE TO HEALTH; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG SELF ADMINISTRATION; FEMALE; HIV INFECTIONS; HOSPITAL ORGANIZATION; HUMAN; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; PSYCHOLOGY; REMINDER SYSTEM; SELF REPORT; STATISTICS AND NUMERICAL DATA; UTILIZATION; VIRUS LOAD;

ADOLESCENT; ADOLESCENT BEHAVIOR; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MEDICATION SYSTEMS; REMINDER SYSTEMS; SELF ADMINISTRATION; SELF REPORT; VIRAL LOAD;

EID: 84939871354     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0806-z     Document Type: Article

References (35)

1. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S149–55.
2. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. Aids. 2001;15(9):1181–3.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
4. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23(5):386–95.
5. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. New Engl J Med. 2002;347(6):385–94.
6. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. Aids. 1999;13(13):1763–9.
7. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167(7):684–91.
8. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445–9.
9. Hadland SE, Milloy MJ, Kerr T, et al. Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users. Aids Patient Care STDs. 2012;26(5):274–80.
10. Martinez J, Harper G, Carleton RA, et al. The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with health care. Aids Patient Care STDS. 2012;26(2):108–15.
11. Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249–55.
12. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M, Ne AMHAR. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. Aids Care. 2001;13(1):27–40.
13. Marhefka SL, Farley JJ, Rodrigue JR, Sandrik LL, Sleasman JW, Tepper VJ. Clinical assessment of medication adherence among HIV-infected children: examination of the treatment interview protocol (TIP). Aids Care. 2004;16(3):323–37.
14. Centers for Disease Control and Prevention. HIV Among Youth. 2013; http://www.cdc.gov/hiv/risk/age/youth/. Accessed June 2013.
15. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2010. HIV Surveillance Supplemental Report 2012; 17 (No. 3, part A); http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed 9/5/2013.
16. MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17(1):86–93.
17. Saberi P, Yuan P, John M, Sheon N, Johnson MO. A pilot study to engage and counsel HIV-positive African American youth via telehealth technology. Aids Patient Care STDS. 2013;27(9):529–32.
18. Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav. 2003;7(1):61–72.
19. Biadgilign S, Deribew A, Amberbir A, Deribe K. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: a qualitative study. Sahara J. 2009;6(4):148–54.
20. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. Plos Med. 2006;3(11):2039–64.
21. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med. 2010;61:169–85.
22. Koenig LJ, Nesheim S, Abramowitz S. Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors. Curr Opin Obstet Gynecol. 2011;23(5):321–7.
23. Andrade ASA, McGruder HF, Wu AW, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis. 2005;41(6):875–82.
24. Mannheimer SB, Morse E, Matts JP, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. Jaids-J Acquir Immune Defic Syndr. 2006;43:S41–7.
25. Safren SA, Hendriksen ES, Desousa N, Boswell SL, Mayer KH. Use of an on-line pager system to increase adherence to antiretroviral medications. Aids Care. 2003;15(6):787–93.
26. Naar-King S, Wright K, Parsons JT, Frey M, Templin T, Ondersma S. Transtheoretical model and substance use in HIV-positive youth. Aids Care. 2006;18(7):839–45.
27. Naar-King S, Arfken C, Frey M, Harris M, Secord E, Ellis D. Psychosocial factors and treatment adherence in paediatric HIV/AIDS. Aids Care. 2006;18(6):621–8.
28. Derogatis LR, Spencer PM. The brief symptom inventory (BSI): administration, and procedures manual-I. Baltimore: Clinical Psychometric Research; 1982.
29. Knight JR, Shrier LA, Bravender TD, Farrell M, VanderBilt J, Shaffer HJ. A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med. 1999;153(6):591–6.
30. Saberi P, Johnson MO, McCulloch CE, Vittinghoff E, Neilands TB. Medication adherence: tailoring the analysis to the data. AIDS Behav. 2011;15(7):1447–53.
31. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 2000.
32. Saberi P, Comfort M, Johnson MO. The relationship between daily organization and adherence to antiretroviral therapy: a qualitative perspective. Jaids-J Acquir Immune Defic Syndr. 2012;61(1):E3–6.
33. Belzer ME, Naar-King S, Olson J, et al. The Use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial. Aids Behav. 2014;18(4):686–96.
34. Outlaw AY, Naar-King S, Tanney M, et al. The initial feasibility of a computer-based motivational intervention for adherence for youth newly recommended to start antiretroviral treatment. Aids Care. 2014;26(1):130–5.
35. Dowshen N, Kuhns LM, Gray C, Lee S, Garofalo R. Feasibility of interactive text message response (ITR) as a novel, real-time measure of adherence to antiretroviral therapy for HIV+ youth. AIDS Behav. 2013;17(6):2237–43.